AIDS overview On the Web
American Roentgen Ray Society Images of AIDS overview
Blogs on AIDS overview</small>
Acquired immune deficiency syndrome (AIDS) is a collection of symptoms and infections resulting from the specific damage to the immune system caused by the human immunodeficiency virus (HIV) in humans, and similar viruses in other species (SIV, FIV, etc.). The late stage of the condition leaves individuals susceptible to opportunistic infections and tumors. Although treatments for AIDS and HIV exist to decelerate the virus's progression, there is currently no known cure. HIV is transmitted through direct contact of a mucous membrane or the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, preseminal fluid, and breast milk. This transmission can come in the form of anal, vaginal or oral sex, blood transfusion, contaminated hypodermic needles, exchange between mother and baby during pregnancy, childbirth, or breastfeeding, or other exposure to one of the above bodily fluids.
Since June 5, 1981, many definitions have been developed for epidemiological surveillance such as the Bangui definition and the 1994 expanded World Health Organization AIDS case definition. However, clinical staging of patients was not an intended use for these systems as they are neither sensitive, nor specific. In developing countries, the World Health Organization staging system for HIV infection and disease, using clinical and laboratory data, is used and in developed countries, the Centers for Disease Control (CDC) Classification System is used.
Human Immunodeficiency virus causes AIDS by depleting CD4+ T helper lymphocytes. T lymphocytes are essential to the immune response and without them, the body cannot fight infections or kill cancerous cells. Thus the weakened immune system allows opportunistic infections and neoplastic processes. The mechanism of CD4+ T cell depletion differs in the acute and chronic phases, to sum it all AIDS has a complex pathophysiology.
Differentiating AIDS from other Diseases
AIDS is an immunodeficiency disease. It should be considered in patient presenting with symptoms of immunodeficiency. AIDS should be distinguished from congenital disorders and considered in the differential diagnosis of childhood immunodeficiency.
The possibility of HIV infection should be considered on a case-by-case basis and other causes of immune suppression must be considered.
Epidemiology and Demographics
Most researchers believe that HIV originated in sub-Saharan Africa during the twentieth century. It is now a pandemic. In 2007, an estimated 33.2 million people lived with the disease worldwide, and it claimed the lives of an estimated 2.1 million people, including 330,000 children. Over three-fourths of these deaths occurred in sub-Saharan Africa, retarding economic growth and destroying human capital Antiretroviral treatment reduces both the mortality and the morbidity of HIV infection, but routine access to antiretroviral medication is not available in all countries.
HIV/AIDS stigma is more severe than that associated with some other life-threatening conditions and extends beyond the disease itself to providers and even volunteers involved with the care of people living with HIV.
In 2010, an estimated 34 million people were living with HIV, of whom more than 30 million were living in low- and middle-income countries.
At the end of 2006, an estimated 1,106,400 persons (range: 1,056,400 – 1,156,400) in the United States were living with HIV. CDC estimates that 56,300 new HIV infections occurred in the United States in 2006. About 1 million Americans have HIV — to a surprise, an estimated 25 percent do not know they have the infection. Therefore, HIV screening is important to both extend their lives and prevent further spreading of the disease.
A number of laboratory tests are important for initial evaluation of HIV-infected paients. Two surrogate markers (CD4 T-cell count (CD4 count), plasma HIV RNA) are routinely used to asses immune function and level of viral viremia.
The pericardium is frequently involved in HIV infections. Also medications used in AIDS therapy can cause EKG changes.
Chest X Ray
Chest X-ray is an extremely common procedure done to evaluate the organs located in the chest area i.e. lungs, heart, and chest wall. It also helps in diagnosing the cause of various symptoms. (for example persistent cough, shortness of breath, chest pain or injury, and fever)
CT scans of chest are important part of diagnosis in HIV patients having pulmonary symptoms. It has an advantage over X-Ray in being more sensitive in detection of early interstitial lung disease, lymphadenopathy, and nodules.
Magnetic resonance imaging or MRI is used in great deal for the care of HIV-positive patients. MRI is the first-choice among neuroimaging modality in the workup for AIDS dementia complex. An MRI is more sensitive than a head CT in determining if a lesion is truly solitary.
Patients infected with the human immunodeficiency virus (HIV) have an increased risk of developing heart disease and they may need an echocardiogram.
The primary goal of antiretroviral therapy (ART) is to reduce HIV-associated morbidity and mortality. This goal is best accomplished by using effective ART to maximally inhibit HIV replication, as defined by achieving and maintaining plasma HIV RNA (viral load) below levels detectable by commercially available assays. Durable viral suppression improves immune function and quality of life, lowers the risk of both AIDS-defining and non-AIDS-defining complications, and prolongs life. Based on emerging evidence, additional benefits of ART include a reduction in HIV-associated inflammation and possibly its associated complications.
HIV infected patients may require surgery to treat infections and diseases associated with the condition. Childbirth and organ transplant are two of the many conditions that may require surgery in a HIV patient.
There is currently no vaccine or cure for HIV or AIDS. The only known methods of prevention are based on avoiding exposure to the virus or, failing that, an antiretroviral treatment directly after a highly significant exposure, called post-exposure prophylaxis (PEP).
Cost-Effectiveness of Therapy
HIV and AIDS retard economic growth by destroying human capital. Without proper nutrition, health care and medicine that is available in developed countries, large numbers of people are falling victim to AIDS. They will not only be unable to work, but will also require significant medical care. The forecast is that this will likely cause a collapse of economies and societies in the region. In some heavily infected areas, the epidemic has left behind many orphans cared for by elderly grandparents.
Future or Investigational Therapies
Research to improve current treatments includes decreasing side effects of current drugs, further simplifying drug regimens to improve adherence, and determining the best sequence of regimens to manage drug resistance. A number of studies have shown that measures to prevent opportunistic infections can be beneficial when treating patients with HIV infection or AIDS. Vaccination against hepatitis A and B is advised for patients who are not infected with these viruses and are at risk of becoming infected. Patients with substantial immunosuppression are also advised to receive prophylactic therapy for Pneumocystis jiroveci pneumonia (PCP), and many patients may benefit from prophylactic therapy for toxoplasmosis and Cryptococcus meningitis as well.
Daily multivitamin and mineral supplements have been found to reduce HIV disease progression among men and women. This could become an important low-cost intervention provided during early HIV disease to prolong the time before antiretroviral therapy is required. Some individual nutrients have also been tried. Anti-retroviral drugs are expensive, and the majority of the world's infected individuals do not have access to medications and treatments for HIV and AIDS. It has been postulated that only a vaccine can halt the pandemic because a vaccine would possibly cost less, thus being affordable for developing countries, and would not require daily treatments. However, after over 20 years of research, HIV-1 remains a difficult target for a vaccine.
- ↑ The Relationship Between the Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome. NIAID. Retrieved on 2008-03-10.
- ↑ Divisions of HIV/AIDS Prevention (2003). HIV and Its Transmission. Centers for Disease Control & Prevention. Retrieved on 2006-05-23.
- ↑ San Francisco AIDS Foundation (2006-04-14). How HIV is spread. Retrieved on 2006-05-23.
- ↑ Guss DA (1994). "The acquired immune deficiency syndrome: an overview for the emergency physician, Part 1". J Emerg Med 12 (3): 375–84. PMID 8040596. Retrieved on 2012-04-27.
- ↑ Gao F, Bailes E, Robertson DL, et al (1999). "Origin of HIV-1 in the Chimpanzee Pan troglodytes troglodytes". Nature 397 (6718): 436–441. doi:10.1038/17130. PMID 9989410.
- ↑ Palella FJ Jr, Delaney KM, Moorman AC, et al (1998). "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators". N. Engl. J. Med 338 (13): 853–860. PMID 9516219.
- ↑ Snyder M, Omoto AM, Crain AL (1999). "Punished for their good deeds: stigmatization for AIDS volunteers". American Behavioral Scientist 42 (7): 1175–1192. doi:10.1177/0002764299042007009.
- ↑ Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, Karon J, Brookmeyer R, Kaplan EH, McKenna MT, Janssen RS (August 2008). "Estimation of HIV incidence in the United States". JAMA 300 (5): 520–9. doi:10.1001/jama.300.5.520. PMID 18677024. Retrieved on 2012-02-23.
- ↑ Greener R (2002). "AIDS and macroeconomic impact", in S, Forsyth (ed.): State of The Art: AIDS and Economics. IAEN, 49–55.
- ↑ Laurence J (2006). "Hepatitis A and B virus immunization in HIV-infected persons". AIDS Reader 16 (1): 15–17. PMID 16433468.
- ↑ Treating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.. Department of Health and Human Services (2007-02-02). Retrieved on 2007-02-05.
- ↑ Fawzi W, Msamanga G, Spiegelman D, Hunter DJ (2005). "Studies of vitamins and minerals and HIV transmission and disease progression". J. Nutrition 135 (4): 938–944. PMID 15795466.
- ↑ (Selenium:) Hurwitz BE, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS, Schneiderman N (2007). "Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial". Arch Intern Med. 167 (2): 148–155. PMID 17242315.
- ↑ (Vitamin C:) Cathcart RR (1984). "Vitamin C in the Treatment of Acquired Immune Deficiency Syndrome". Medical Hypotheses 14 (4): 423-433. doi:10.1016/0306-9877(84)90149-X. PMID 6238227.
- ↑ 15.0 15.1 15.2 Ferrantelli F, Cafaro A, Ensoli B (2004). "Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines". Curr Opin Biotechnol. 15 (6): 543–556. PMID 15560981.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies